CAR-T細胞療法の2030年までの市場予測：薬剤タイプ、標的抗原、用途、エンドユーザー、地域別の世界分析

Stratistics MRCによると、世界のCAR-T細胞療法市場は2023年に33億米ドルを占め、予測期間中にCAGR 30.5％で成長し、2030年には218億米ドルに達すると予測されています。

CAR-T細胞療法は、キメラ抗原受容体T細胞療法の略で、ある種のがんの治療に用いられる画期的な免疫療法です。患者自身のT細胞（免疫細胞の一種）を遺伝子改変し、その表面にキメラ抗原受容体（CAR）を発現させる。このプロセスは通常、白血球除去法（leukapheresis）と呼ばれる方法で患者の血液からT細胞を採取することから始まる。次に、これらのT細胞は、CARと呼ばれる特定の受容体を表面に発現するように実験室で遺伝子操作されます。これらのレセプターは、通常がん細胞の表面に存在する特定のタンパク質を認識し、結合するように設計されています。

世界がん研究基金インターナショナルが発表したがんデータによると、2020年には世界中で新たに白血病が474,519例、多発性骨髄腫が176,404例、リンパ腫が627,439例発生するといいます。

増加するがんの有病率

CAR-T技術の有望な進歩にもかかわらず、がん罹患率の増加は重大な課題を突きつけています。人口の高齢化、環境要因、ライフスタイルの変化などの要因がこの傾向に寄与しています。効果的ながん治療への需要が高まるにつれ、CAR-T療法分野のヘルスケアプロバイダーや研究者にとって、この有病率の上昇への対処が必須となっています。このように、市場はがん患者の増加という懸念すべき動向を経験しています。

承認された治療法の数が限られている

急速に発展しているCAR-T細胞療法の分野では、承認された治療法は限られています。これらの治療法は、白血病やリンパ腫を含む特定の種類の血液がんに対して顕著な有効性を示しています。しかし、高コスト、複雑な製造工程、適応拡大や安全性プロファイル改善のためのさらなる調査の必要性などのため、市場は比較的制約を受けたままです。

技術の進歩

CAR-T細胞療法の進歩はがん治療に革命をもたらし、個別化免疫療法のソリューションを提供しています。貸し出されたウイルスベクター設計や自動化された細胞処理システムなどの強化された製造技術は、生産を合理化し、スケーラビリティを向上させ、コストを削減します。CARコンストラクトの標的修飾は腫瘍特異性を高め、オフターゲット効果を低減し、治療効果を高める。

高い製造コスト

CAR-T細胞市場は、主に複雑で労働集約的なプロセスにより、多大な製造コストに直面しています。CAR-T細胞の製造には、高度な細胞工学技術、広範な品質管理対策、専門的なインフラが必要となります。さらに、各治療は個々の患者に合わせて行われるため、治療の個別化という性質もコストに拍車をかけています。このような高いコストは、CAR-T細胞療法の普及とアクセシビリティに課題をもたらし、より幅広い患者層への利用を制限しています。

COVID-19の影響：

COVID-19の流行はCAR-T細胞療法市場に大きな影響を与え、臨床試験、製造、患者アクセスに混乱をもたらしました。サプライチェーンの混乱と病院の収容能力の低下により、治療が遅れ、市場の成長が妨げられています。さらに、リソースの転用やCOVID-19治療の優先順位が、CAR-T療法の開発や展開から注意を逸らしています。課題はあるもの、免疫療法と革新的治療への注目の高まりが、長期的には市場の回復と成長を促進する可能性があります。

予測期間中、チサゲンロイセルセグメントが最大となる見込み

予測期間中、ティサゲンロイセル・セグメントが最大となる見込みです。特定のがん細胞を標的とするように設計されたこの薬剤は、ある種の白血病やリンパ腫の患者において顕著な効果を示しています。その承認は免疫療法における重要なマイルストーンとなり、従来の治療法を使い果たした患者に新たな希望をもたらしました。この成功により、Tisagenlecleucelは瞬く間にCAR-T細胞療法市場における中心的な存在となり、この分野における進歩やさらなる研究の推進力となっています。

予測期間中、リンパ腫分野のCAGRが最も高くなると予想される

リンパ腫分野は、免疫療法の進歩により、予測期間中に最も高いCAGRが見込まれます。CAR-T細胞療法は、患者自身の免疫細胞を、がん細胞をよりよく認識し攻撃するように改変するものです。この個別化アプローチは、様々なリンパ腫サブタイプ、特に従来の治療に反応しなかった患者において有望な結果を示しています。現在進行中の調査と臨床試験により、リンパ腫の治療市場はさらなる成長が見込まれています。

最大のシェアを占める地域

予測期間中、北米が最大の市場シェアを占めると予測されます。個別化医療に重点を置いたCAR-T療法は、白血病やリンパ腫を含む様々な種類のがんの治療で人気を集めています。同地域の強固なヘルスケア・インフラは、支持的な規制の枠組みと相まって市場拡大を促進しています。さらに、製薬企業と学術機関との協力関係は、この有望な分野における技術革新の加速に寄与しており、市場の明るい見通しを約束しています。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域のCAGRが最も高いと予測されます。各国におけるがんの有病率の上昇に加え、認知度の向上と診断の改善により、CAR-T細胞療法の恩恵を受ける可能性のある患者層が拡大しています。各国で実施されているCAR-T細胞療法の臨床試験の数も大幅に増加しています。これらの臨床試験では、さまざまな種類のがんにおけるさまざまなCAR-T治療の安全性と有効性が評価されており、この地域におけるこの分野の発展に貢献しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のCAR-T細胞療法市場：薬剤タイプ別

• ブレクスカブタゲン・オートロイセル
• アクシカブタゲン・シロロイセル
• ティサゲンルクルーセル
• 他の種類の薬剤

第6章 世界のCAR-T細胞療法市場：標的抗原別

• CD19
• B細胞成熟抗原（BCMA）
• GD2
• CD20
• その他の標的抗原

第7章 世界のCAR-T細胞療法市場：用途別

• 急性リンパ性白血病
• リンパ腫
• 慢性リンパ性白血病
• 濾胞性リンパ腫
• 肝細胞がん
• 結腸直腸がん
• その他の用途

第8章 世界のCAR-T細胞療法市場：エンドユーザー別

• がん治療センター
• 病院
• その他のエンドユーザー

第9章 世界のCAR-T細胞療法市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Gilead Sciences Inc.
• Bristol-Myers Squibb
• Novartis AG
• Cartesian Therapeutics Inc.
• Merck & Co. Inc.
• Intellia Therapeutics
• Juno Therapeutics Inc.
• Bluebird Bio Inc.
• Sorrento Therapeutics Inc.
• Autolus Therapeutics
• Caribou Biosciences Inc.
• Miltenyi Biotech
• Celgene Corporation
• Aurora Biopharma Inc.
• Pfizer, Inc.

List of Tables

• Table 1 Global CAR T-Cell Therapy Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 4 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 5 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 6 Global CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 7 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 8 Global CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 9 Global CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 11 Global CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 12 Global CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 13 Global CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 14 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 15 Global CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 16 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 17 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 18 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 19 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 20 Global CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 21 Global CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 22 Global CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 23 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 24 Global CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 25 North America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 26 North America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 27 North America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 28 North America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 29 North America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 30 North America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 31 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 32 North America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 33 North America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 34 North America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 35 North America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 36 North America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 37 North America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 38 North America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 39 North America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 40 North America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 41 North America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 42 North America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 43 North America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 44 North America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 45 North America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 46 North America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 47 North America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 48 North America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 49 Europe CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 50 Europe CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 51 Europe CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 52 Europe CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 53 Europe CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 54 Europe CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 55 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 56 Europe CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 57 Europe CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 58 Europe CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 59 Europe CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 60 Europe CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 61 Europe CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 62 Europe CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 63 Europe CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 64 Europe CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 65 Europe CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 66 Europe CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 67 Europe CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 68 Europe CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 69 Europe CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 70 Europe CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 71 Europe CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 72 Europe CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 73 Asia Pacific CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 74 Asia Pacific CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 75 Asia Pacific CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 76 Asia Pacific CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 77 Asia Pacific CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 78 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 79 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 80 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 81 Asia Pacific CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 82 Asia Pacific CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 83 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 84 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 85 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 86 Asia Pacific CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 87 Asia Pacific CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 88 Asia Pacific CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 89 Asia Pacific CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 90 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 91 Asia Pacific CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 92 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 93 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 94 Asia Pacific CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 95 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 96 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 97 South America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 98 South America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 99 South America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 100 South America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 101 South America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 102 South America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 103 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 104 South America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 105 South America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 106 South America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 107 South America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 108 South America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 109 South America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 110 South America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 111 South America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 112 South America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 113 South America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 114 South America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 115 South America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 116 South America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 117 South America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 118 South America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 119 South America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 120 South America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 121 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 122 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 123 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 124 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 125 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 126 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 127 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 128 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 129 Middle East & Africa CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 130 Middle East & Africa CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 131 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 132 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 133 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 134 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 135 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 136 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 137 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 138 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 139 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 140 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 141 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 142 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 143 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 144 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global CAR-T Cell Therapy Market is accounted for $3.3 billion in 2023 and is expected to reach $21.8 billion by 2030 growing at a CAGR of 30.5% during the forecast period. CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a groundbreaking form of immunotherapy used in the treatment of certain types of cancer. It involves genetically modifying a patient's own T cells (a type of immune cell) to express chimeric antigen receptors (CARs) on their surface. The process typically starts by collecting T cells from the patient's blood through a process called leukapheresis. These T cells are then genetically engineered in a laboratory to express specific receptors called CARs on their surface. These receptors are designed to recognize and bind to specific proteins, typically found on the surface of cancer cells.

According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Despite the promising advancements in CAR-T technology, the rise in cancer incidence poses significant challenges. Factors such as aging populations, environmental factors, and lifestyle changes contribute to this trend. As the demand for effective cancer treatments grows, addressing this rising prevalence becomes imperative for healthcare providers and researchers in the field of CAR-T therapy. Thus, the market is experiencing a concerning trend with an increasing prevalence of cancer cases.

Restraint:

Limited number of approved therapies

In the rapidly evolving field of CAR-T cell therapy, only a limited number of treatments have gained approval. These therapies have shown remarkable efficacy in treating certain types of blood cancers, including leukemia and lymphoma. However, the market remains relatively constrained due to high costs, complex manufacturing processes, and the need for further research to expand indications and improve safety profiles.

Opportunity:

Advancements in technology

Advancements in CAR-T cell therapy have revolutionized cancer treatment, offering personalized immunotherapy solutions. Enhanced manufacturing techniques, such as lent viral vector design and automated cell processing systems, streamline production, improving scalability and reducing costs. Targeted modifications to CAR constructs enhance tumour specificity and reduce off-target effects, boosting therapeutic efficacy.

Threat:

High manufacturing costs

The market faces significant manufacturing costs, primarily due to the complex and labor-intensive process involved. Manufacturing CAR-T cells requires sophisticated cell engineering techniques, extensive quality control measures, and specialized infrastructure. Additionally, personalized nature of the therapy adds to the expenses, as each treatment is tailored to individual patients. These high costs pose challenges for widespread adoption and accessibility of CAR-T cell therapy, limiting its availability to a broader patient population.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the CAR-T cell therapy market, causing disruptions in clinical trials, manufacturing, and patient access. Supply chain disruptions and reduced hospital capacity have delayed treatments and hindered market growth. Additionally, diverted resources and prioritization of COVID-19 care have diverted attention from CAR-T therapy development and deployment. Despite challenges, increased focus on immunotherapy and innovative treatments may drive market recovery and growth in the long term.

The tisagenlecleucel segment is expected to be the largest during the forecast period

The tisagenlecleucel segment is expected to be the largest during the forecast period. Engineered to target specific cancer cells, it has shown remarkable efficacy in patients with certain types of leukemia and lymphoma. Its approval marked a significant milestone in immunotherapy, offering new hope for patients who have exhausted conventional treatments. With its success, Tisagenlecleucel has quickly become a pivotal player in the CAR-T cell therapy market, driving advancements and further research in the field.

The lymphoma segment is expected to have the highest CAGR during the forecast period

The lymphoma segment is expected to have the highest CAGR during the forecast period driven by advancements in immunotherapy. CAR-T cell therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. This personalized approach has shown promising results in various lymphoma subtypes, particularly in patients who have not responded to conventional treatments. With ongoing research and clinical trials, the market for therapy in lymphoma is poised for further growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. With a focus on personalized medicine, CAR-T therapies are gaining traction for treating various types of cancers, including leukemia and lymphoma. The region's robust healthcare infrastructure, coupled with supportive regulatory frameworks, fosters market expansion. Moreover, collaborations between pharmaceutical companies and academic institutions contribute to accelerating innovation in this promising field, promising a bright outlook for the market.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The rising prevalence of cancer in countries, coupled with growing awareness and improved diagnosis, was creating a larger pool of patients who could potentially benefit from CAR-T cell therapy. There was a significant increase in the number of clinical trials for CAR-T cell therapies being conducted in countries. These trials were evaluating the safety and efficacy of various CAR-T treatments across different types of cancer, contributing to the advancement of the field in the region.

Key players in the market

Some of the key players in CAR-T Cell Therapy market include Gilead Sciences Inc., Bristol-Myers Squibb, Novartis AG, Cartesian Therapeutics Inc., Merck & Co. Inc., Intellia Therapeutics, Juno Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics Inc., Autolus Therapeutics, Caribou Biosciences Inc., Miltenyi Biotech, Celgene Corporation, Aurora Biopharma Inc. and Pfizer, Inc.

Key Developments:

In December 2023, Bristol-Myers Squibb announced that it received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

In May 2023, Autolus Therapeutics plc announced that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress.

Drug Types Covered:

• Brexucabtagene Autoleucel
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Other Drug Types

Target Antigens Covered:

• CD19
• B-Cell Maturation Antigen (BCMA)
• GD2
• CD20
• Other Target Antigens

Applications Covered:

• Acute Lymphocytic Leukemia
• Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hepatocellular Carcinoma
• Colorectal Cancer
• Other Applications

End Users Covered:

• Cancer Treatment Centers
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global CAR T-Cell Therapy Market, By Drug Type

• 5.1 Introduction
• 5.2 Brexucabtagene Autoleucel
• 5.3 Axicabtagene Ciloleucel
• 5.4 Tisagenlecleucel
• 5.5 Other Drug Types

6 Global CAR T-Cell Therapy Market, By Target Antigen

• 6.1 Introduction
• 6.2 CD19
• 6.3 B-Cell Maturation Antigen (BCMA)
• 6.4 GD2
• 6.5 CD20
• 6.6 Other Target Antigens

7 Global CAR T-Cell Therapy Market, By Application

• 7.1 Introduction
• 7.2 Acute Lymphocytic Leukemia
• 7.3 Lymphoma
• 7.4 Chronic Lymphocytic Leukemia
• 7.5 Follicular Lymphoma
• 7.6 Hepatocellular Carcinoma
• 7.7 Colorectal Cancer
• 7.8 Other Applications

8 Global CAR T-Cell Therapy Market, By End User

• 8.1 Introduction
• 8.2 Cancer Treatment Centers
• 8.3 Hospitals
• 8.4 Other End Users

9 Global CAR T-Cell Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Gilead Sciences Inc.
• 11.2 Bristol-Myers Squibb
• 11.3 Novartis AG
• 11.4 Cartesian Therapeutics Inc.
• 11.5 Merck & Co. Inc.
• 11.6 Intellia Therapeutics
• 11.7 Juno Therapeutics Inc.
• 11.8 Bluebird Bio Inc.
• 11.9 Sorrento Therapeutics Inc.
• 11.10 Autolus Therapeutics
• 11.11 Caribou Biosciences Inc.
• 11.12 Miltenyi Biotech
• 11.13 Celgene Corporation
• 11.14 Aurora Biopharma Inc.
• 11.15 Pfizer, Inc.